[go: up one dir, main page]

WO1992006113A3 - DERIVES DE gp160 ET VACCINS A BASE DE gp160 OU D'UN DE SES DERIVES, CONTENANT UN ADJUVANT - Google Patents

DERIVES DE gp160 ET VACCINS A BASE DE gp160 OU D'UN DE SES DERIVES, CONTENANT UN ADJUVANT Download PDF

Info

Publication number
WO1992006113A3
WO1992006113A3 PCT/EP1991/001810 EP9101810W WO9206113A3 WO 1992006113 A3 WO1992006113 A3 WO 1992006113A3 EP 9101810 W EP9101810 W EP 9101810W WO 9206113 A3 WO9206113 A3 WO 9206113A3
Authority
WO
WIPO (PCT)
Prior art keywords
derivative
adjuvant
derivatives
vaccines based
uncleavable
Prior art date
Application number
PCT/EP1991/001810
Other languages
English (en)
Other versions
WO1992006113A2 (fr
Inventor
Wijnendale Frans Van
Moncef Slaoui
Claudine Bruck
Myriam Francotte
Suzy Kummert
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909021175A external-priority patent/GB9021175D0/en
Priority claimed from GB919106048A external-priority patent/GB9106048D0/en
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Priority to KR1019930700978A priority Critical patent/KR100194079B1/ko
Priority to AU85109/91A priority patent/AU654970B2/en
Publication of WO1992006113A2 publication Critical patent/WO1992006113A2/fr
Publication of WO1992006113A3 publication Critical patent/WO1992006113A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Nouvelles formes de gp160, sensiblement non clivables, et formulations de vaccins contenant de la gp160 ou un de ses dérivés, comportant un adjuvant 3D-Mpl. Les compositions s'utilisent pour le traitement immunotherapeutique et immunoprophylactique des infections VIH.
PCT/EP1991/001810 1990-09-28 1991-09-21 DERIVES DE gp160 ET VACCINS A BASE DE gp160 OU D'UN DE SES DERIVES, CONTENANT UN ADJUVANT WO1992006113A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1019930700978A KR100194079B1 (ko) 1990-09-28 1991-09-21 Hiv 감염 예방 또는 치료용 제약학적 조성물 및 이의 제조방법
AU85109/91A AU654970B2 (en) 1990-09-28 1991-09-21 Derivatives of gp160 and vaccines based on gp160 or a derivative thereof, containing an adjuvant

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB909021175A GB9021175D0 (en) 1990-09-28 1990-09-28 Novel compounds
GB9021175.6 1990-09-28
GB9106048.3 1991-03-21
GB919106048A GB9106048D0 (en) 1991-03-21 1991-03-21 Vaccines

Publications (2)

Publication Number Publication Date
WO1992006113A2 WO1992006113A2 (fr) 1992-04-16
WO1992006113A3 true WO1992006113A3 (fr) 1992-08-20

Family

ID=26297726

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1991/001810 WO1992006113A2 (fr) 1990-09-28 1991-09-21 DERIVES DE gp160 ET VACCINS A BASE DE gp160 OU D'UN DE SES DERIVES, CONTENANT UN ADJUVANT

Country Status (10)

Country Link
EP (2) EP0644201A1 (fr)
JP (1) JPH06501151A (fr)
KR (1) KR100194079B1 (fr)
AU (1) AU654970B2 (fr)
CA (1) CA2092827A1 (fr)
IE (1) IE913385A1 (fr)
MX (1) MX9101275A (fr)
NZ (1) NZ239948A (fr)
PT (1) PT99063B (fr)
WO (1) WO1992006113A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197311B1 (en) 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
US6620414B2 (en) 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
EP0684838A1 (fr) * 1993-02-19 1995-12-06 Smithkline Beecham Corporation Compositions de vaccin contre la grippe, contenant un lipide a de monophosphoryle desacyle en position 3-o
CZ289476B6 (cs) * 1993-03-23 2002-01-16 Smithkline Beecham Biologicals (S.A.) Očkovací přípravek a způsob jeho výroby
US6039957A (en) * 1993-12-10 2000-03-21 United States Of America, As Represented By The Department Of Health And Human Services Oligomeric HIV-1 envelope glycoproteins
US6171596B1 (en) 1993-12-10 2001-01-09 The United States Of America As Represented By The Department Of Health And Human Services Oligomeric HIV-1 envelope glycoproteins
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6368604B1 (en) 1997-09-26 2002-04-09 University Of Maryland Biotechnology Institute Non-pyrogenic derivatives of lipid A
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
WO2001000232A2 (fr) * 1999-06-29 2001-01-04 Smithkline Beecham Biologicals S.A. Vaccin
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0335635A1 (fr) * 1988-03-28 1989-10-04 The Board Of Trustees Of The Leland Stanford Junior University Protéine de l'enveloppe d'HIV qui a subi une mutation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0335635A1 (fr) * 1988-03-28 1989-10-04 The Board Of Trustees Of The Leland Stanford Junior University Protéine de l'enveloppe d'HIV qui a subi une mutation

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Cell, vol. 53, 8th April 1988, Cell Press, J.M. McCUNE et al.: "Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus", pages 55-67, see the whole document *
Chemical Abstracts, vol. 112, 1990, (Columbus, Ohio, US), H.G. GUO et al.: "Characterization of an HIV-1 point mutant blocked in envelope glycoprotein cleavage", see page 191, abstract no. 92736b, & VIROLOGY 1990, 174(1), 217-24, see the whole abstract *
Chemical Abstracts, vol. 112, 1990, (Columbus, Ohio, US), V. BOSCH et al.: "Mutational analysis of the human immunodeficiency virus type 1 env gene product proteolytic cleavage site", see page 487, abstract no. 233824t, & J. VIROL. 1990, 64(5), 2337-44, see the whole abstract *
F. BOREK: "Frontiers of Biology", vol. 25, 1972, North-Holland Publishing Co., (Amsterdam, NL), page 122, see paragraph 4.8, first paragraph *
Int. Conf. AIDS, 20-23 June 1990, vol. 6, no. 1, S.-L. HU et al.: "Immunization with HIV-1 gp160 enhances HIV-specific immune responses elicited by vaccinia-HIV, recombinant virus", abstract no. 10034390, see the whole document *
Proceedings of the National Academy of Sciences of USA, vol. 87, January 1990, P.L. EARL et al.: "Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein", pages 648-652, see the whole document *
Protein Engineering, vol. 2, no. 3, September 1988, (Eynsham, Oxford, GB), M.P. KIENY et al.: "Improved antigenicity of the HIV env protein by cleavage site removal", pages 219-225, see the whole document *

Also Published As

Publication number Publication date
AU654970B2 (en) 1994-12-01
EP0644201A1 (fr) 1995-03-22
JPH06501151A (ja) 1994-02-10
MX9101275A (es) 1992-05-04
NZ239948A (en) 1993-07-27
KR100194079B1 (ko) 1999-06-15
PT99063B (pt) 1999-07-30
KR930702527A (ko) 1993-09-09
PT99063A (pt) 1992-08-31
AU8510991A (en) 1992-04-28
CA2092827A1 (fr) 1992-03-29
WO1992006113A2 (fr) 1992-04-16
EP0550485A1 (fr) 1993-07-14
IE913385A1 (en) 1992-04-08

Similar Documents

Publication Publication Date Title
CH614718A5 (en) Process for the preparation of glucosamine derivatives
UA40597C2 (uk) Вакцинна композиція,спосіб лікування ссавців, що страждають або сприйнятливі до інфекції, спосіб лікування ссавців, що страждають на рак, спосіб одержання вакцинної композиції, композиція ад'ювантів
IL174413A0 (en) Immunological adjuvants compounds
AU5457596A (en) Adjuvants for viral vaccines
AU1979599A (en) (neisseria meningitidis) antigens
WO2002009746A8 (fr) Composition vaccinale
MA22842A1 (fr) Procede de preparation de compositions de vaccin.
CA2132547A1 (fr) Vaccins renfermant des vesicules d'agents tensioactifs non ioniques
WO2003051392A3 (fr) Vaccin
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
AU5457496A (en) Adjuvants for viral vaccines
WO1992006113A3 (fr) DERIVES DE gp160 ET VACCINS A BASE DE gp160 OU D'UN DE SES DERIVES, CONTENANT UN ADJUVANT
EP2275122A3 (fr) Vaccins contre le streptococcus pneumoniae à base de protéine
IL130075A0 (en) A vaccine for eliciting an immune response to an antigen in an animal
NO912825D0 (no) Fremgangsmaate for fremstilling av cokonjugate vaksiner omfattende immunogenisk protein, hiv-beslektede peptider og anioniske grupper.
CA2022420A1 (fr) Vaccin contre escherichia coli
WO2003024354A3 (fr) Interleukine 12 utilisee comme adjuvant de vaccin veterinaire
BR9107294A (pt) Derivados do GP160 e vacinas baseadas no GP160 ou um derivado do mesmo, contendo um adjuvante
TW275632B (fr)
AU3853495A (en) Immunogenic compositions
WO2001097841A3 (fr) Qs-21 et il-12 utilises comme combinaison d'adjuvants
WO2000050073A3 (fr) Immunoadjuvant de lps de caulobacter
AU1362895A (en) Pasteurella multocida toxoid vaccines
WO2000052045A3 (fr) Peptides immunogenes derives de mage-3 presentes par le complexe majeur d'histocompatibilte (mch) de categorie ii et utilisations associees
HU9801705D0 (en) Streptococcus equi vaccine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1991916067

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2092827

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1991916067

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1991916067

Country of ref document: EP